Department of Laboratory Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
Thromb Res. 2010 May;125(5):438-43. doi: 10.1016/j.thromres.2009.12.004. Epub 2009 Dec 22.
Congenital blood coagulation factor XII (FXII) deficiency is a rare coagulation disease and an autosomal recessive trait. It is found by chance in many cases. We identified a novel mutation (Lys346Asn) in the FXII gene of a patient with FXII deficiency, designated as Factor XII Ofunato.
The proband was a 75-year-old Japanese woman with a prolonged activated partial thromboplastin time (52.8s). The FXII activity and antigen were greatly reduced (activity, 5%; antigen, 4.5%). We analyzed FXII gene of this patient using a direct sequencing method and characterized mutant FXII through in vitro expression studies.
Sequence analysis of the FXII gene revealed a G-->C point mutation at nucleotide 9845, resulting in Lys346 (AAG)-->Asn (AAC) replacement in the catalytic domain. Expression studies in Chinese hamster ovary cells demonstrated that mutant FXII (346N-FXII) showed a lower level of accumulation in the cells than wild-type. Secretion of 346N-FXII was greatly reduced in culture medium. We also investigated mRNA expression levels of wild-type and 346N-FXII in transfected cells using quantitative RT-PCR. Both mRNA expressions were equivalent levels. Pulse-chase experiments showed that 346N-FXII was extensively degraded intracellularly compared to wild-type. Using membrane-permeable inhibitors, we observed that degradation occurred in the pre-Golgi compartment and that proteasome apparently plays a central role in this process.
These results show that most 346N-FXII is degraded intracellularly through endoplasmic reticulum-associated degradation as the protein quality control system, resulting in an insufficient secretion phenotype.
先天性凝血因子 XII(FXII)缺乏症是一种罕见的凝血疾病,为常染色体隐性遗传特征。在许多情况下,它是偶然发现的。我们在一名 FXII 缺乏症患者的 FXII 基因中发现了一种新的突变(Lys346Asn),将其命名为 FXII Ofunato。
先证者是一名 75 岁的日本女性,其活化部分凝血活酶时间延长(52.8s)。FXII 活性和抗原显著降低(活性为 5%,抗原为 4.5%)。我们使用直接测序法分析了该患者的 FXII 基因,并通过体外表达研究对突变的 FXII 进行了特征分析。
FXII 基因序列分析显示核苷酸 9845 处发生 G-->C 点突变,导致催化域中的赖氨酸 346(AAG)被天冬酰胺(AAC)取代。在中国仓鼠卵巢细胞中的表达研究表明,突变型 FXII(346N-FXII)在细胞中的积累水平低于野生型。346N-FXII 的分泌在培养基中大大减少。我们还使用定量 RT-PCR 研究了转染细胞中野生型和 346N-FXII 的 mRNA 表达水平。两种 mRNA 表达水平相当。脉冲追踪实验表明,与野生型相比,346N-FXII 在细胞内广泛降解。使用膜通透性抑制剂,我们观察到降解发生在高尔基氏体前区,并且蛋白酶体显然在这个过程中起核心作用。
这些结果表明,大多数 346N-FXII 通过内质网相关降解作为蛋白质质量控制系统在细胞内被降解,导致分泌不足的表型。